Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A bioartificial pancreas to treat type 1 diabetes: optimization of cell survival and function in preclinical and clinical phases (BIOSID)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,United Kingdom,France,United Kingdom,France,Belgium
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2016-12-31
Duration (months): 48.0
Total project cost (EUR): 6793606.4
EU funding (EUR): 5169502.8
Participants: 8
Project status: CLOSED

MAILPAN (MAcroencapsulation of PANcreatic Islets) is a prototype of bioartificial pancreas usable in the human designed to treat type 1 diabetic patients. The prototype was developed along different stages since 1996 and led to the creation of the SME called Defymed in 2011. Next step is now to bring the prototype to the pre-clinical and clinical phases necessary to the ensuing commercialization of MAILPAN whose ultimate goal is to improve the life of at least 20 million persons in the world while providing positive effects on healthcare management and expenses, the environment and the competitiveness of the biomaterials industry. In order to reach this goal, CeeD and Defymed gathered a consortium made of seven partners from academia, clinical/public health research sector and industry/SMEs from three different European countries –Belgium, France and UK. The expertise gathered include encapsulation techniques, islet isolation, cell engineering, islet transplantation, islet preconditioning, surgical implantation, and medium formulation; items that are complementary and necessary to the implementation of the present project proposal. The project proposal of a 48-month duration intends to bring the most modern and up to date improvements that the bioartificial pancreas still needs and can receive such as to enhance cells survival inside the device by formulating a new adapted cell culture medium, to further lower the rejection risk by studying the biocompatibility and anti-inflammatory mechanisms, to test the prototype in small and large animal models, and to secure its further use in humans. Safety and bio-compatibility of MAILPAN device combined to the islets/pseudo-islets, will be assessed, in respect to the applied regulatory directives.

Keywords: type 1 diabetes,biomaterials,implant,pancreas,transplantation,therapy,survival,media formulation,pre-clinical and clinical phases
Paving the way towards HIV eradication/control (HIT HIDDEN HIV)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Germany,Switzerland,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2016-10-31
Duration (months): 47.0
Total project cost (EUR): 6584613.72
EU funding (EUR): 5029854.0
Participants: 5
Project status: CLOSED

Major advances in HIV/AIDS treatment regimens have fundamentally altered the natural history of the disease and sharply reduced HIV-related morbidity and mortality in countries where such treatments are accessible. The most notable advance is the use of combination antiretroviral therapy or ART. However, ART is unable to achieve virus eradication or “sterilizing cure”. Indeed, in most cases, viral rebound is observed after ART interruption. Thus, life-long treatment is currently needed to control HIV. Drug resistance, cumulative side effects and high cost, represent major drawbacks of such treatments. The persistence of HIV in treated patients results from the establishment of a viral reservoir insensitive to ART and poorly visible to the immune system. Thus, understanding HIV persistence and developing drugs able to flush out HIV, in order to achieve viral eradication or “sterilizing cure” remain outstanding challenges. Two main lines of research are being proposed. The first starts from the recent discovery by partners of this consortium of the immune-modulator Samhd1 as the cellular factor restricting HIV-1 infection in myeloid cells. We will explore a role for Samhd1 in immune activation and inflammation, and its impact on the balance between viral replication and persistence. To understand further HIV persistence, we will study the molecular mechanisms underlying post-integrative latency. The second aims at identifying and optimizing novel naturally occurring inducers of HIV reactivation. Additionally, a novel non-human primate model will be developed, allowing the study of viral persistence in vivo by tracking latently-infected cells. The project aims at (i) increasing knowledge on the contribution of immune activation and inflammation to HIV persistence (ii) deciphering the cellular and molecular mechanisms of viral persistence (iii) translating this basic knowledge into novel targets to achieve a cure for HIV/AIDS.

Keywords: hiv/aids,persistence,latency,immune activation,inflammation
Intervention Research On Health Literacy among Ageing population (IROHLA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,Netherlands,Germany,Ireland,United Kingdom,Belgium,Italy,Germany,Finland,Hungary,Greece,Italy,Germany,Netherlands,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2015-11-30
Duration (months): 36.0
Total project cost (EUR): 3721218.46
EU funding (EUR): 2896632.3
Participants: 22
Project status: CLOSED

The IROHLA project aims at innovating the conceptual understanding of health literacy interventions in Europe. Health literacy is one of the social determinants of health and reflects how well persons can understand, digest and critically reflect on information with regard to health and illness. People with sufficient health literacy skills are able to act proactively on health issues, take their own decisions and manage health and illnesses well. Right now in EU countries 10% – 30% of the population has insufficient health literacy skills, which is associated with higher morbidity and mortality, while utilisation of health services is higher and treatment outcomes are poorer than average. Health literacy is a major issue amongst the ageing population in Europe. Tackling health literacy problems in the ageing population leads to social innovation and leads to reduction of costs of healthcare. The IROHLA project will investigate health literacy interventions among the ageing population and will draw lessons from other sectors, e.g. the social sector and the commercial sector. By involving scientist from medical, paramedical field, social and behavioural sciences, communication sciences and other related fields, the project will be truly multidisciplinary. The project will involve stakeholders from the ageing population and from levels of government. The project will develop a comprehensive approach for health literacy among the ageing population, based on synergetic effects of empowerment and health literacy communication, which countries can apply in prevention, curative services and care services. The project will concentrate on modern media and e-health applications. The final product will be a guideline for policy and practice with (max) 20 high potential interventions that together will improve health literacy of the ageing population. The project will make a direct contribution to the European Innovation Partnership on Active and Healthy Ageing.

Keywords: health ageing,health literacy,illiteracy,social innovation,empowerment,communication,synergetic action,intersectoral collaboration,e-health,cost reduction,consumer participation
Hydroxitirosol, a new generation of microbicides targeting HIV through antiviral and anti-inflammatory pathways (AIM-HIV)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,France,Italy
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2015-05-31
Duration (months): 30.0
Total project cost (EUR): 2346372.74
EU funding (EUR): 1827081.0
Participants: 4
Project status: CLOSED

Since the first cases of AIDS were reported 30 years ago, HIV remains a difficult target for the research field. Although there is no cure for AIDS, HIV infection can be prevented, however in many countries across the world access to prevention and treatment services is limited. Global leaders have pledged to work towards universal access to HIV prevention and care, so that millions of deaths can be averted.There is much that can be done to reduce the impact of AIDS, beginning with the prevention of HIV transmission. In this sense, the main objective of this proposal is to decrease the virus spread avoiding the infection among women. Diminishing HIV transmission among women is a key step towards undermine the virus presence since it will not be transmitted to the new generation of children and to their partners. AIM-HIV project aims to reduce the transmission of HIV in countries with high incidence through the development of a new effective and low-cost microbicide based on 5-Hydroxytyrosol. For this aim, the proposed Consortium will be composed by an SME company with strong research and development capacities and broad experience in the field of hydroxytyrosol, SEPROX Biotech S.L., and three European research groups with a profound knowledge on HIV and cellular HIV infection and integration: Instituto de Salud Carlos III (ISCIII), Commissariat à l’énergie atomique et aux energies alternatives (CEA) and Università Vita-Salute San Raffaele (USR). The duration of the project will be 30 months, with a total budget of 2,331,804€ and a requested grant of 1,827,081€. The estimated EU contribution going to the SME SEPROX is a 25.3% of the total requested EU contribution for the project as a whole. The Consortium has already contacted with organizations and institutions that have a huge interest in the project´s result and will have an important role for assuring the proper dissemination of the final product which will be widely accessible and manage by women themselves

Keywords: anti-hiv activity,5-hydroxitirosol,microbicides,anti-inflammatory,sub-saharan africa,hiv prevention
Development of a prophylactic treatment for the prevention of fetal/neonatal alloimmune thrombocytopenia (FNAIT) (PROFNAIT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Norway,Denmark,Germany,Germany,Sweden,Sweden,Germany,Denmark
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-08-01
End date: 2019-01-31
Duration (months): 78.0
Total project cost (EUR): 7781185.01
EU funding (EUR): 5986000.0
Participants: 12
Project status: CLOSED

Objective--The project aims to develop an anti HPA-1a immunoglobulin (IgG), Tromplate® that can prevent post delivery immunisation of the mother against the Human Platelet Antigen-1a (HPA-1a). This prophylactic treatment will prevent Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) in the fetus/newborn in subsequent pregnancies. FNAIT--FNAIT is a rare but potentially serious condition which affects about 4,000 fetuses and newborns a year in EU-27 and which may result in severe bleeding, intracranial hemorrhage, fetal death or lifelong disability. FNAIT may develop when the mother and the fetus have different platelet surface antigens, most commonly HPA-1a. Transferral of HPA-1a antigen from the fetus may cause immunisation of the mother and the anti-HPA-1a antibodies she develops may in turn destroy the platelets of subsequent HPA-1a positive fetuses/newborns and cause FNAIT. Today, no good treatment of FNAIT exists. Rationale--Previously, it was believed that the pregnant woman develops antibodies early in the first pregnancy with the implication that FNAIT could not be prevented. However, a study conducted by the applicants of more than 100,000 pregnancies revealed that HPA-1a antibody formation most often takes place in association with or after delivery. Therefore, anti-HPA-1a IgG given to the mother shortly after birth should prevent her immune system from generating harmful anti-HPA-1a antibodies. This concept is analogous to the use of anti(D) for Rhesus D prophylaxis. Activities--The project elements: manufacturing of Tromplate® using the process for producing anti(D); screening for HPA-1a negative and pregnant women and clinical Phase II/III studies investigating the efficacy and safety of Tromplate®. Relevance to the work program−The prophylactic Tromplate® treatment has obtained orphan drug status in Europe. FNAIT represents a significant health care expense for the society and a great burden for the affected children and their families.

Keywords: fetal and neonatal alloimmune thrombocytopenia hpa-1a antigen screening drug development prevention
2013 Epilepsy Research Forum (ERFIP2013)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: United States,Ireland
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-07-01
End date: 2013-12-31
Duration (months): 18.0
Total project cost (EUR): 255501.0
EU funding (EUR): 100000.0
Participants: 3
Project status: CLOSED

Epilepsy is a brain disorder that is characterised by recurrent episodes of cerebral dysfunction, that is, seizures which are caused by excessive electrical discharges of nerve cells. It is one of the most common serious disorders of the brain. Six million people in Europe have Epilepsy and approximately 300,000 new cases are diagnosed each year. The Epilepsy Research Forum 2013 will seek to contribute to the debate on the coordination of research at national and European Union level as well and to focus on research achievements made to date and the opportunities for further advances. By bringing together a wide spectrum of stakeholders it is hoped that national and European epilepsy research networks will be better coordinated and targeted. With an expected attendance of 500 stakeholders, the Conference will stimulate debate on, in the first instance, promoting research into improving the diagnosis and treatment of epilepsy. The Conference programme will also aim at improving awareness and reducing stigma, in what will essentially be a multifaceted conference engaging clinicians and patients alike. The specific objectives are: -to promote and discuss the opportunities for coordinated, targeted and precise innovative research efforts that would build on the significant gains made by basic and clinical research in the past -the 2013 Forum, whilst aimed primarily at facilitating research opportunities in epilepsy, will also seek to address the optimal standards of care for people with epilepsy which are still unequally distributed in European Union

Keywords: epilepsy,research,awareness,treatment,epileptology,epileptologist,optimal standards of care
Biomarker Research Alliance for Diagnosing Heart Disease in the Ageing European Population (BESTAGEING)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Estonia,Italy,Germany,Sweden,Germany,France,Netherlands,Germany,Spain,Ukraine,Greece,Netherlands,Spain,Belgium
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-02-01
End date: 2018-01-31
Duration (months): 60.0
Total project cost (EUR): 15194316.0
EU funding (EUR): 10906368.0
Participants: 21
Project status: CLOSED

The ageing of the European population represents a rapidly rising social and economic challenge. Especially cardiovascular morbidity increases with age, but unfortunately, elderly patients are often difficult to diagnose due to confounding factors, leading to uncertainties in clinical decision making with huge impact on patients’ outcomes. Hence, there is an unmet need for novel biomarkers for more accurate diagnosis, risk assessment, and clinical outcome prediction for both acute and chronic cardiovascular diseases in the elderly. The BestAgeing consortium aims to improve this lack of diagnostic capabilities by developing and validating innovative omics-based biomarkers particularly for elderly patients – supporting healthy ageing in Europe. Our study design addresses the most frequent and severe cardiovascular diseases of elderly patients by incorporating the appropriate disease cohorts and biomaterials from European populations. We aim to develop new omics-assays to diagnose cardiovascular disease, estimate risk, and monitor the response to treatment in elderly. This is envisaged to enable a more stratified and economic delivery of medicine. We expect that BestAgeing will generate novel European medical technologies that can improve the efficacy and efficiency of our care for elderly patients, which will also impact on socioeconomic wealth in Europe.

Keywords: heart diseases,biomarkers,metabolomics,mirnas,protein markers,risk assesment,clinical outcome,multi-marker strategies,age-related cardiovascular diseases
Systems biology approaches to cervical pre-cancer and cancer (SYSTEMCERV)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Ireland,Germany,Germany,Hungary
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2014-10-31
Duration (months): 24.0
Total project cost (EUR): 3144641.87
EU funding (EUR): 2368884.0
Participants: 5
Project status: CLOSED

Currently cervical histology is the gold standard procedure in the field. However, there is a need for alternative approaches and specific biomarkers to aid objective CIN lesion grading and to identify true high grade cervical disease, especially in the advent of primary HPV screening and widespread HPV vaccination. Panel of mRNA markers has been developed using systems biology and datamining tools and has demonstrated high specificity [93%] and sensitivity [88%] for detecting CIN 2-3 lesions. Clinical data supports its application as a cervical cancer grading biomarker as well. Our goal is to ascertain the utility of this novel panel and extend it using systems biology approaches with experimentally and computationally derived proteomic biomarkers in cervical pre cancer and cancer disease, for more accurate diagnosis of CIN disease. Toward that goal we establish a general framework for validation of proteomic biomarkers. This will be achieved by combining advanced technologies in a robust and time-effective way, including DNA array to protein array copying, Human Combinatorial Antibody Library of phage display and iRIfS, imaging Reflectometric Interference Spectroscopy technology. Systems biology approached would focus on both the existing and new markers and will use this framework rapid validation. Systems biology exploration of some specific pathways is justified by our previous data, that the CIN1/CIN2+ discrimination could be related to some given pathways. The proposed approach potentially reduce costs of cervical clinical studies providing a reliable, quantitative, multi-content diagnostic approaches and results in reducing the number of colposcopic events. Cytology specimens will be of greater clinical utility and will result in earlier detection of disease. Molecular characterization of CIN lesions provides a basis for re-definition of histological categories.

Keywords: cervical cancer,biomarker,clincal study,histology
Quantifying aerosol-cloud-climate effects by regime (QUAERERE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Earth system science
Countries involved: Germany
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2012-10-01
End date: 2017-09-30
Duration (months): 60.0
Total project cost (EUR): 1448160.0
EU funding (EUR): 1448160.0
Participants: 1
Project status: CLOSED

Global climate change is widely considered one of the main concerns of humankind. However, predictions are highly uncertain, with no substantial improvement since more than three decades. They are hampered by the huge uncertainty of climate forcing, which is dominated by the uncertainty in anthropogenic aerosol-cloud-climate effects (“aerosol indirect effects”). The goal of QUAERERE (Latin for researching) is a reliable, observations-based, global quantification of these effects, which would also imply a constraint on climate sensitivity and thus climate predictions. This goal is now reachable combining recent advances in different disciplines: (i) a decade-long satellite dataset involving retrievals of the relevant quantities is now available, complemented by a complete aerosol dataset from a new reanalysis; (ii) on the basis of high-resolved numerical weather pre­diction models, which include parameterisations of aerosol cycles and cloud-precipitation microphysics, cloud-system resolving simulations at a regional scale are now possible; reliable simulations beyond idealised cases are thus possible. These tools are complemented by comprehensive global climate models and reference ob­servations from ground-based sites. The problem in aerosol-cloud-climate effects is in its complexity: Various processes counteract each other, and large spatiotemporal variability of clouds buffers the forcing effects. QUAERERE proposes a two-fold “divide-and-conquer” approach to this complex problem: (i) aerosol-cloud-climate effects will be investigated by regime; this allows to circumvent the problem of aerosol-cloud-climate ef­fects being buffered when averaging over different regimes; and (ii) by investigating individual terms con­tributing to the aerosol-cloud-climate effects separately; this allows to analyse individual statistical relation­ship in satellite observations and model results consistently, and to perform model sensitivity studies for cause-effect attribution.

Keywords: climate change,radiative forcing,aerosol,aerosol-cloud-climate effects,aerosol indirect effects,climate modeling,climate sensitivity,satellite observations